We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Moderate Alcohol Use on Hepatitis C Virus (HCV) Progression

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00205075
First Posted: September 20, 2005
Last Update Posted: December 9, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University of Wisconsin, Madison
September 13, 2005
September 20, 2005
December 9, 2015
August 2004
June 2008   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00205075 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Impact of Moderate Alcohol Use on Hepatitis C Virus (HCV) Progression
The Use of Validated Measures of Alcohol Intake to Measure the Impact of Moderate Alcohol Consumption on Hepatic Fibrogenesis in Individuals Infected With Hepatitis C
The purpose of this study is to determine the effect of moderate alcohol intake on liver disease caused by HCV in terms of speed of progression as compared to those not drinking alcohol.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
outpatient with HCV not receiving or planning treatment but is receiving standard of care monitoring every 3 months, abstinent or drinking
  • Hepatic Fibrogenesis
  • Hepatitis C
Not Provided
  • Case
  • Control
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
47
June 2008
June 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Outpatient with HCV who is not receiving or planning treatment but is receiving standard of care monitoring every 3 months and is either abstinent from alcohol or drinking only moderately

Exclusion Criteria:

  • HIV co-infection
  • Treated within the past 6 months
  • History (hx) of other liver disease
  • Alcohol use greater than 30 g/day or history of binge drinking in the last year
  • Decompensated liver disease
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00205075
H-2004-0161
Not Provided
Not Provided
Not Provided
University of Wisconsin, Madison
University of Wisconsin, Madison
Not Provided
Principal Investigator: Adnan Said, MD University of Wisconsin, Madison
University of Wisconsin, Madison
December 2015